In contrast, other reports utilizing external beam/brachytherapy irradiation have not observed any worse loco-regional recurrence outcomes in patients with triple negative/basal type of breast cancer (36–41), young age (42–44) or infiltrating lobular histologies (45–51) when compared to older patients with non- lobular or HER2/neu positive tumors. The gene discussed is ERBB2; the disease is breast carcinoma.